A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects

Objective: Ertugliflozin is approved in the US and European Union as a stand-alone product for adults with type 2 diabetes mellitus as once daily (QD) dosing. The approved fixed-dose combination (FDC) of ertugliflozin and immediate-release metformin is dosed twice daily (BID). This study assessed st...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Int J Clin Pharmacol Ther
Hlavní autoři: Dawra, Vikas Kumar, Liang, Yali, Shi, Haihong, Bass, Almasa, Hickman, Anne, Terra, Steven G., Zhou, Susan, Cutler, David, Sahasrabudhe, Vaishali
Médium: Artigo
Jazyk:Inglês
Vydáno: Dustri-Verlag Dr. Karl Feistle 2019
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6528385/
https://ncbi.nlm.nih.gov/pubmed/30802200
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5414/CP203343
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky